微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688321 微芯生物

已收盘 05-10 15:00:00

{"stockData":{"symbol":"688321","market":"SH","secType":"STK","nameCN":"微芯生物","latestPrice":23.75,"timestamp":1715324400000,"preClose":24.4,"halted":0,"volume":3961671,"delay":0,"floatShares":411000000,"shares":411000000,"eps":0.2505,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.65,"latestTime":"05-10 15:00:00","open":24.45,"high":24.66,"low":23.65,"amount":94750100,"amplitude":0.0414,"askPrice":23.76,"askSize":37,"bidPrice":23.75,"bidSize":3,"shortable":0,"etf":0,"ttmEps":0.2505,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1715563800000},"adr":0,"adjPreClose":24.4,"symbolType":"stock_kcb","openAndCloseTimeList":[[1715304600000,1715311800000],[1715317200000,1715324400000]],"highLimit":26.84,"lowLimit":21.96,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":411286794,"pbRate":6.24,"roa":"--","roe":"--","epsLYR":0.2176,"committee":-0.439815,"marketValue":9768000000,"floatMarketCap":9768000000,"peRate":94.810382,"changeRate":-0.0266,"turnoverRate":0.0096,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-05-13。","afterMarket":{"amount":0,"volume":0,"close":23.75,"buyVolume":0,"sellVolume":0,"time":1715326439505,"indexStatus":"已收盘 05-10 15:30:00","preClose":24.4}},"requestUrl":"/m/hq/s/688321","defaultTab":"news","newsList":[{"id":"2434388170","title":"非酒精性脂肪性肝炎(NASH)概念盘中拉升，微芯生物涨1.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2434388170","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2434388170?lang=zh_cn&edition=full","pubTime":"2024-05-09 09:49","pubTimestamp":1715219349,"startTime":"0","endTime":"0","summary":"05月09日，非酒精性脂肪性肝炎(NASH)概念盘中拉升，截至09点49分，非酒精性脂肪性肝炎(NASH)概念整体指数上涨0.50%，报1119.150点。从个股上来看，该概念的成分股中，微芯生物涨1.97%，众生药业、华东医药、诺泰生物涨幅居前。从资金上来看，截止发稿，非酒精性脂肪性肝炎(NASH)概念主力净流入为-2276.37万，其中迈瑞医疗受到资金热捧，主力净流入868.89万；拉长时间线来看，该板块近20日主力资金净流入-2.50亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405090949097a58deeb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405090949097a58deeb&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433579852","title":"微芯生物(688321)深度报告：原创新药领域先行者 持续耕耘出芯篇","url":"https://stock-news.laohu8.com/highlight/detail?id=2433579852","media":"华西证券股份有...","top":-1,"share":"https://www.laohu8.com/m/news/2433579852?lang=zh_cn&edition=full","pubTime":"2024-05-07 08:11","pubTimestamp":1715040709,"startTime":"0","endTime":"0","summary":"公司通过积极打开西达本胺的销售下沉渠道，已和62 家一级经销商达成合作，共覆盖全国27 个省份。据公司2024 年一季报： 报告期内，公司营业收入同比增长22.60%，主要为西格列他钠的销售收入增长所致。2023 年12 月，西达本胺PTCL 适应症第四次进入医保目录，医保支付价格下调6%；报告期内，西达本胺销量同比增长8%，销售收入同比持平。归属于上市公司股东的净利润同比亏损收窄43.63%。产品上市申请及获批不及预期风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405070811548ae2db50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405070811548ae2db50&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433444513","title":"5月6日微芯生物涨5.20%，工银优选对冲灵活配置混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2433444513","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433444513?lang=zh_cn&edition=full","pubTime":"2024-05-06 16:33","pubTimestamp":1714984401,"startTime":"0","endTime":"0","summary":"证券之星消息，5月6日微芯生物涨5.20%创60日新高，收盘报23.05元，换手率1.75%，成交量7.2万手，成交额1.63亿元。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为工银优选对冲灵活配置混合发起A。工银优选对冲灵活配置混合发起A目前规模为0.71亿元，最新净值1.0198，较上一交易日上涨0.3%，近一年上涨5.37%。该公募基金现任基金经理为刘子豪。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050616453987d7ce58&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050616453987d7ce58&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433482460","title":"华福证券：给予微芯生物买入评级，目标价位34.11元","url":"https://stock-news.laohu8.com/highlight/detail?id=2433482460","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433482460?lang=zh_cn&edition=full","pubTime":"2024-05-06 10:48","pubTimestamp":1714963684,"startTime":"0","endTime":"0","summary":"华福证券有限责任公司盛丽华近期对微芯生物进行研究并发布了研究报告《24年有望迎来估值+业绩+数据读出多个拐点》，本报告对微芯生物给出买入评级，认为其目标价位为34.11元，当前股价为22.65元，预期上涨幅度为50.6%。23Q4西达本胺PTCL适应症第四次进入医保目录，医保支付价格下调6%。24Q1西达本胺销量同比增长8%，销售收入同比持平。最新盈利预测明细如下：该股最近90天内共有3家机构给出评级，买入评级3家；过去90天内机构目标均价为27.6。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050600005799.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431361815","title":"微芯生物(688321.SH)：西达本胺联合R-CHOP治疗弥漫大B细胞淋巴瘤适应症获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2431361815","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431361815?lang=zh_cn&edition=full","pubTime":"2024-04-30 15:44","pubTimestamp":1714463066,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微芯生物 发布公告，近日，公司收到国家药品监督管理局核准签发的《药品注册证书》，西达本胺联合R-CHOP治疗弥漫大B细胞淋巴瘤适应症获批上市。公告称，西达本胺联合R-CHOP治疗弥漫大B细胞淋巴瘤适应症的上市获批，是西达本胺继外周T细胞淋巴瘤和乳腺癌获批后的第三个适应症，将进一步扩大西达本胺的治疗范围，预计将对公司未来经营业绩产生积极的影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116174.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430039018","title":"微芯生物(688321)3月31日股东户数2.12万户，较上期减少1.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430039018","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430039018?lang=zh_cn&edition=full","pubTime":"2024-04-28 17:06","pubTimestamp":1714295201,"startTime":"0","endTime":"0","summary":"证券之星消息，近日微芯生物披露，截至2024年3月31日公司股东户数为2.12万户，较2月29日减少268.0户，减幅为1.25%。在化学制药行业个股中，微芯生物股东户数低于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.3万户。从股价来看，2024年2月29日至2024年3月31日，微芯生物区间涨幅为10.21%，在此期间股东户数减少268.0户，减幅为1.25%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404281714198b5d59be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404281714198b5d59be&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430080247","title":"微芯生物最新公告：一季度净亏损1830.46万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430080247","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430080247?lang=zh_cn&edition=full","pubTime":"2024-04-28 16:19","pubTimestamp":1714292391,"startTime":"0","endTime":"0","summary":"微芯生物披露2024年第一季度报告，报告期实现营业收入1.31亿元，同比增长22.60%；归属于上市公司股东的净利润-1830.46万元；基本每股收益-0.0448元。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042800003721.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430820770","title":"微芯生物(688321.SH)：一季度净亏损1830.46万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430820770","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2430820770?lang=zh_cn&edition=full","pubTime":"2024-04-28 15:45","pubTimestamp":1714290313,"startTime":"0","endTime":"0","summary":"格隆汇4月28日丨微芯生物(688321.SH)公布2024年第一季度报告，报告期实现营业收入1.31亿元，同比增长22.60%；归属于上市公司股东的净利润-1830.46万元；归属于上市公司股东的扣除非经常性损益的净利润-2197.61万元；基本每股收益-0.0448元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404281545168b5d0a86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404281545168b5d0a86&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429513555","title":"海通国际：给予微芯生物增持评级，目标价位26.33元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429513555","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429513555?lang=zh_cn&edition=full","pubTime":"2024-04-23 10:43","pubTimestamp":1713840215,"startTime":"0","endTime":"0","summary":"海通国际证券集团有限公司Kehan Meng近期对微芯生物进行研究并发布了研究报告《公司年报点评：2024，进入微芯原创新药收获之年》，本报告对微芯生物给出增持评级，认为其目标价位为26.33元，当前股价为20.36元，预期上涨幅度为29.32%。2023年公司西达本胺营收4.7亿元，同比基本持平，西格列他钠新药放量营收4225万元，同比增长167.0%，技术授权许可营收662万元，同比下滑84.9%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300020678.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429184737","title":"北向资金4月22日净卖出微芯生物21.78万股 连续7日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2429184737","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429184737?lang=zh_cn&edition=full","pubTime":"2024-04-23 09:30","pubTimestamp":1713835831,"startTime":"0","endTime":"0","summary":"4月22日，北向资金减持微芯生物21.78万股连续7日减持。截止当日收盘，沪股通共持有微芯生物176.36万股，占流通股0.42%。沪股通减持金额前五个股分别为农业银行、中国石化、XD万华化、药明康德、长江电力。微芯生物近5个交易日上涨4.24%，沪股通累计减持79.20万股；近20个交易日上涨16.71%，沪股通累计减持154.52万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042309363887a37db1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042309363887a37db1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429918159","title":"海通国际发布微芯生物研报","url":"https://stock-news.laohu8.com/highlight/detail?id=2429918159","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2429918159?lang=zh_cn&edition=full","pubTime":"2024-04-23 09:05","pubTimestamp":1713834300,"startTime":"0","endTime":"0","summary":"海通国际04月23日发布研报称，给予微芯生物（688321.SH，最新价：20.67元）优于大市评级。评级理由主要包括：1）2023年公司业绩表现平平；2）2024年起，公司将进入原创新药收获之年；3）西达本胺+PD1多项数据展露优势，有望开启“IO+西达本胺”时代。风险提示：研发进展不达预期，商业化进展不达预期。AI点评：微芯生物近一个月获得2份券商研报关注，买入1家，平均目标价为29.67元，与最新价20.67元相比，高9元，目标均价涨幅43.54%。（文章来源：每日经济新闻）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404230906518b48118f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404230906518b48118f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429162899","title":"微芯生物04月22日主力资金流入68万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2429162899","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429162899?lang=zh_cn&edition=full","pubTime":"2024-04-22 15:18","pubTimestamp":1713770308,"startTime":"0","endTime":"0","summary":"04月22日, 微芯生物股价涨0.15%，报收20.67元，成交金额7990万元，换手率0.93%，振幅3.05%，量比0.65。微芯生物今日主力资金净流入68万元，连续5日净流入，上一交易日主力净流入210万元，今日环比减少67.62%。该股近5个交易日上涨4.24%，主力资金累计净流入2686万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出507万元，其中净流出天数为9日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221528228b44ee02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221528228b44ee02&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428680358","title":"微芯生物(688321)：2024 进入微芯原创新药收获之年","url":"https://stock-news.laohu8.com/highlight/detail?id=2428680358","media":"海通证券股份有...","top":-1,"share":"https://www.laohu8.com/m/news/2428680358?lang=zh_cn&edition=full","pubTime":"2024-04-19 16:18","pubTimestamp":1713514722,"startTime":"0","endTime":"0","summary":"2023 年公司西达本胺营收4.7 亿元，同比基本持平，西格列他钠新药放量营收4225 万元，同比增长167.0%，技术授权许可营收662 万元，同比下滑84.9%。2024 年起，公司将进入原创新药收获之年。2023 年1 月纳入医保目录用于2 型糖尿病，2023 年11 月公司披露西格列他钠新增生产线获GMP 认证通过。根据公司24 年4 月1 日投资者关系活动记录表，西达本胺DLBCL 适应症大概率2024 年上半年获批。2024 年公司多项数据读出及递交上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191618548794b23d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191618548794b23d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428355354","title":"微芯生物04月18日主力资金流入1431万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2428355354","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428355354?lang=zh_cn&edition=full","pubTime":"2024-04-18 15:19","pubTimestamp":1713424767,"startTime":"0","endTime":"0","summary":"04月18日, 微芯生物股价涨2.87%，报收20.45元，成交金额1.64亿元，换手率1.95%，振幅6.49%，量比1.45。微芯生物今日主力资金净流入1431万元，连续3日净流入，上一交易日主力净流入608万元，今日环比增加135.36%。该股近5个交易日下跌1.59%，主力资金累计净流入679万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出1121万元，其中净流出天数为10日。该行业中净流入前三个股分别为江苏吴中、悦康药业、微芯生物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418153311878ea8ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418153311878ea8ec&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428832965","title":"非酒精性脂肪性肝炎(NASH)概念盘中拉升，微芯生物涨3.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428832965","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428832965?lang=zh_cn&edition=full","pubTime":"2024-04-18 09:58","pubTimestamp":1713405509,"startTime":"0","endTime":"0","summary":"04月18日，非酒精性脂肪性肝炎(NASH)概念盘中拉升，截至09点58分，非酒精性脂肪性肝炎(NASH)概念整体指数上涨1.13%，报993.570点。从个股上来看，该概念的成分股中，微芯生物涨3.12%，福瑞股份、众生药业、华东医药涨幅居前。从资金上来看，截止发稿，非酒精性脂肪性肝炎(NASH)概念主力净流入为-1411.05万，其中众生药业受到资金热捧，主力净流入546.72万；拉长时间线来看，该板块近20日主力资金净流入-14.07亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041809582987e818b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041809582987e818b1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428455545","title":"微芯生物(688321)：西达本胺卷土重来 联合治疗实体瘤潜力巨大","url":"https://stock-news.laohu8.com/highlight/detail?id=2428455545","media":"华福证券有限责...","top":-1,"share":"https://www.laohu8.com/m/news/2428455545?lang=zh_cn&edition=full","pubTime":"2024-04-18 00:00","pubTimestamp":1713369600,"startTime":"0","endTime":"0","summary":"经测算西达本胺在血液瘤的销售峰值超10 亿元，为公司贡献稳定现金流。三药方案西达本胺+信迪利单抗+贝伐珠单抗联合治疗MSS/pMMR 晚期结直肠癌的II 期数据显示相比三线标准疗法显著提升疗效。理论上西达本胺联合免疫治疗联用具有一定的普适性，有较大的实体瘤应用潜力，预计西达本胺联合替雷利珠一线非小细胞肺癌II 期临床数据24 年内读出。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418154401878ec22a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418154401878ec22a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427518308","title":"微芯生物获融资买入0.18亿元，近三日累计买入0.37亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2427518308","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2427518308?lang=zh_cn&edition=full","pubTime":"2024-04-16 08:25","pubTimestamp":1713227130,"startTime":"0","endTime":"0","summary":"4月15日，沪深两融数据显示，微芯生物获融资买入额0.18亿元，居两市第476位，当日融资偿还额0.07亿元，净买入1100.57万元。最近三个交易日，11日-15日，微芯生物分别获融资买入0.13亿元、0.06亿元、0.18亿元。融券方面，当日融券卖出3.42万股，净卖出1.82万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404160827098b28061e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404160827098b28061e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427046373","title":"微芯生物大跌5.05% 主力净流出1308万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2427046373","media":"智选洞察","top":-1,"share":"https://www.laohu8.com/m/news/2427046373?lang=zh_cn&edition=full","pubTime":"2024-04-15 14:03","pubTimestamp":1713161033,"startTime":"0","endTime":"0","summary":"04月15日，微芯生物股价大幅下跌，截至14点03分，微芯生物下跌5.05%，报19.74元/股，突破10元整数关口，成交1.02亿元，换手率1.23%。资金动向截止发稿，微芯生物获得主力净流出1308万元，其中超大单流出893万元，大单流出413万元。北向资金方面，微芯生物04月12日获得北向资金减持12.84万股，截至04月12日，北向资金当前共持有微芯生物275.06万股，市值5429万元，持股占流通股比为0.66%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041514041979208060&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041514041979208060&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427097412","title":"非酒精性脂肪性肝炎(NASH)概念盘中跳水，微芯生物跌3.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427097412","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427097412?lang=zh_cn&edition=full","pubTime":"2024-04-15 09:58","pubTimestamp":1713146304,"startTime":"0","endTime":"0","summary":"04月15日，非酒精性脂肪性肝炎(NASH)概念盘中跳水，截至09点58分，非酒精性脂肪性肝炎(NASH)概念整体指数下跌0.50%，报999.180点。从个股上来看，该概念的成分股中，微芯生物跌3.08%，福瑞股份、众生药业、诺泰生物跌幅居前。从资金上来看，截止发稿，非酒精性脂肪性肝炎(NASH)概念主力净流入为-888.47万，其中迈瑞医疗受到资金热捧，主力净流入1151.25万；拉长时间线来看，该板块近20日主力资金净流入-12.82亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415095824861e5914&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415095824861e5914&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426719271","title":"微芯生物04月12日遭主力抛售402万元 环比增加105.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426719271","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426719271?lang=zh_cn&edition=full","pubTime":"2024-04-12 15:17","pubTimestamp":1712906277,"startTime":"0","endTime":"0","summary":"04月12日, 微芯生物股价涨0.05%，报收20.79元，成交金额9070万元，换手率1.06%，振幅2.98%，量比0.48。微芯生物今日主力资金净流出402万元，上一交易日主力净流出196万元，今日环比增加105.10%。该股近5个交易日下跌0.67%，主力资金累计净流出3731万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出1473万元，其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240412152644876d52f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240412152644876d52f4&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2019-08-12","address":"广东省深圳市南山区西丽街道曙光社区智谷产业园B栋21F-24F","stockEarnings":[{"period":"1week","weight":0.084},{"period":"1month","weight":0.1299},{"period":"3month","weight":0.4947},{"period":"6month","weight":-0.0258},{"period":"1year","weight":0.0389},{"period":"ytd","weight":0.082}],"companyName":"深圳微芯生物科技股份有限公司","boardCode":"AI0027","perCapita":"19446股","boardName":"医药制造业","registeredCapital":"41128万元","compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.042},{"period":"3month","weight":0.1007},{"period":"6month","weight":0.038},{"period":"1year","weight":-0.0468},{"period":"ytd","weight":0.0604}],"survey":"　　深圳微芯生物科技股份有限公司的主营业务为药物技术开发、相关成果商业应用，主要产品均为自主研究发现与开发的新分子实体且作用机制新颖的原创新药。公司获得2020中国医药工业信息中心颁发的“中国医药新锐创新力量”奖；2020年10月，公司获 得“2020中国化学制药行业成长型优秀企业品牌”与“2020中国化学制药行业抗肿瘤和免疫调节剂类优秀产品品牌”两个奖项。","serverTime":1715405438514,"listedPrice":20.43,"stockholders":"21150人(较上一季度减少1.25%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供微芯生物(688321)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"微芯生物,688321,微芯生物股票,微芯生物股票老虎,微芯生物股票老虎国际,微芯生物行情,微芯生物股票行情,微芯生物股价,微芯生物股市,微芯生物股票价格,微芯生物股票交易,微芯生物股票购买,微芯生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供微芯生物(688321)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}